About the project
Did you know that diabetic patients are 2.5 times more likely to develop heart failure than people without diabetes? The CARDIATEAM project explored diabetic cardiomyopathy and whether it differs from heart issues experienced by people without diabetes. In their clinical study, CARDIATEAM enrolled over 1 200 people with a range of cardiometabolic disorders, including people with diabetes, and followed them for three years.
CARDIATEAM stands out for its use of advanced computational methods, including unsupervised machine learning and clustering, to analyse the large and complex dataset. These techniques help identify subgroups of patients with similar disease patterns and uncover hidden links between risk factors and heart dysfunction. Early analyses have highlighted the importance of metabolic and immune pathways in the development of diabetic cardiomyopathy, pointing to potential new avenues for diagnosis and treatment.
About the event
In conversation with CARDIATEAM discussed the results of the clinical study as well as bringing together insights from the public and the private side of the project. The discussion focused on how these results will shape the diagnosis and treatment of people with diabetes and heart failure moving forwards.
Speakers
Head of the “Senescence, Metabolism and cardiovascular diseases” Team
INSERM/APHP
Vice President, Early Phase Cardiovascular Research (R&D) & Cardiometabolic Clinical Trials
Eli Lilly
